SEC ownership of RECURSION PHARMACEUTICALS, INC.

Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001601830.

Comparable stake leader

BlackRock, Inc.

Disclosed value leader

ARK Investment Management LLC

Comparable rows

7/50

Latest evidence

16 Nov 2026

Ownership snapshot CIK-linked ownership evidence from parsed SEC filings. 3 signals
Comparable ownership rows
7 of 50
Meaning: Rows with safely comparable ownership %
Latest 13D/G holder
BlackRock, Inc.
Source: Latest parsed Schedule 13D/G stake
Latest parsed ownership date
16 Nov 2026
Freshness: Most recent filing date in this holder set
Issuer Names, identifiers, and filing context for this profile. 2 identity fields
Issuer CIK
0001601830
Issuer location
Salt Lake City, UT

Ownership snapshot

Top shareholders of RECURSION PHARMACEUTICALS, INC. (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
BlackRock, Inc.
Disclosed value leader
ARK Investment Management...
Comparable rows
7/50
Latest evidence
16 Nov 2026
13D/G 13F 3/4/5 Lead comparable stake: 8.5% 43 rows are not safely comparable across share classes. 13D/G row: BlackRock, Inc. Showing 1-8 of 50 holder rows.

Quick read

BlackRock, Inc. leads the comparable SEC ownership view at 8.5%.

7 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens BlackRock, Inc.'s linked filing trail.
Comparable ownership Top 5
BlackRock, Inc. 8.5%
ARK Investment Management LLC 8.4%
VANGUARD PORTFOLIO MANAGEMENT LLC 6%
STATE STREET CORP 5.6%
VANGUARD CAPITAL MANAGEMENT LLC 5.1%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-8 of 50 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
BlackRock, Inc.
13D/G
8.5%
Reported 13D/G · 30 Jun 2026
$163,467,690
44,541,605 shares
+$24,661,695 30 Jun 2026
ARK Investment Management LLC
13F 13D/G
Company
8.4%
Reported 13D/G · 30 Sep 2026
$184,796,952
44,745,025 shares
— 30 Sep 2026
VANGUARD PORTFOLIO MANAGEMENT LLC
13F 13D/G
Company · Vanguard Portfolio Management
6%
Reported 13D/G · 30 Jun 2026
$147,904,159
35,812,145 shares
— 30 Sep 2026
STATE STREET CORP
13F 13D/G
Company · STATE STREET CORPORATION
5.6%
Reported 13D/G · 30 Sep 2026
$123,904,696
30,001,137 shares
— 30 Sep 2026
VANGUARD CAPITAL MANAGEMENT LLC
13D/G 13F
Vanguard Capital Management · Company
5.1%
Reported 13D/G · 30 Jun 2026
$95,209,099
26,744,129 shares
$0 30 Jun 2026
BAILLIE GIFFORD & CO
13D/G 13F
Company
4.6%
Reported 13D/G · 31 Dec 2025
$97,239,635
23,774,972 shares
$0 31 Dec 2025
RA CAPITAL MANAGEMENT, L.P.
13D/G
2%
Reported 13D/G · 31 Dec 2024
$44,187,549
7,725,096 shares
$0 31 Dec 2024
Lux Ventures IV, L.P.
3/4/5
Former 10% Owner
—
denominator unverified
$137,710,376
13,021,519 shares
— 07 Dec 2021
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Forms 3/4/5 flow

Insider trading overview

Net insider flow leans to selling over the last 12 months. Net value: -$7,430,966.

Buys
$0
Insiders: 0
Sells
$7,430,966
Insiders: 6
Net
-$7,430,966
Shares: -1,864,811
Window
Last 12 months
4 rolling buckets
Buy value Sell value
Shares: 0 Shares: 1,864,811
Window (months) Buy shares Sell shares Buy value Sell value Net value
0-3 0 167,408 $0 $701,222 -$701,222
3-6 0 171,937 $0 $623,788 -$623,788
6-9 0 466,254 $0 $1,564,830 -$1,564,830
9-12 0 1,059,212 $0 $4,541,125 -$4,541,125

Reporting owners

Insider holders from Forms 3/4/5

Showing 1-20 of 24 reporting-owner rows connected to RECURSION PHARMACEUTICALS, INC.. Open a relationship link for the CIK-to-CIK filing trail.

Rows
24
Largest Forms 3/4/5 holder
Lux Ventures IV, L.P.
Net 12M change
-$7.43MFull value: -$7,430,967 · USD · 12-month change
Latest report
16 Nov 2026
Name Relationship Holdings Value Past Year Net Change Change % Valuation Report Date
Lux Ventures IV, L.P. Former 10% Owner $137,710,376 Mixed 07 Dec 2021
Mubadala Investment Co PJSC 10%+ Owner $137,333,970 Mixed 02 Mar 2023
Zachary Bogue Director, 10%+ Owner $39,514,048 Mixed 03 Jul 2023
Blake Borgeson Director $23,544,953 -$4,495,200 -16% Filing P/S 03 Nov 2026
MIC Capital Partners (Public) Parallel Cayman, LP 10%+ Owner $14,688,335 Mixed 01 Nov 2021
Dean Y. Li Director $12,743,752 Mixed 01 Oct 2026
Michael Secora Chief Financial Officer $9,186,510 Mixed 15 Nov 2024
Najat Khan CEO and President, Director $8,206,619 -$806,534 -8.9% Median 16 Nov 2026
Ben R. Taylor Chief Financial Officer $4,321,813 -$157,704 -3.5% Median 16 Nov 2026
David Hallett Chief Scientific Officer $4,200,953 Median 16 Nov 2026
Christopher Gibson Director $3,199,120 -$1,818,400 -36% Filing P/S 05 Jun 2026
Tina Marriott President and COO $3,129,811 Mixed 15 Nov 2024
Shafique Virani Chief Business Officer $1,446,192 Mixed 16 Jan 2024
David J. Mauro Chief Medical Officer $1,392,024 Mixed 15 Nov 2024
Ramona Doyle Chief Medical Officer $1,280,811 Mixed 16 May 2022
Zavain Dar Director $900,511 Mixed 01 Oct 2026
Ph.D. Robert Hershberg MD Director $810,780 -$125,000 -13% Filing P/S 06 Oct 2026
Franziska Michor Director $661,514 Mixed 17 Jun 2026
Fred Hassan Director $646,997 Median 02 Nov 2026
CHAVEZ R. MARTIN Director $529,780 Mixed 01 Apr 2024

Recent insider transactions for RECURSION PHARMACEUTICALS, INC.

Showing up to 300 recent insider transactions from the last 12 months.

Insider Symbol Class Transaction % SEC-reported value SEC-reported price Shares Shares owned Date Ownership
Ben R. Taylor RXRX Class A Common Stock Tax liability -2.33% -25,018 1,046,444 16 Nov 2026 Direct
David Hallett RXRX Class A Common Stock Tax liability -2.55% -26,657 1,017,180 16 Nov 2026 Direct
Najat Khan RXRX Class A Common Stock Tax liability -4.14% -85,815 1,987,075 16 Nov 2026 Direct
Blake Borgeson RXRX Class A Common Stock Sale -0.65% -$155,200 $3.88 -40,000 6,068,287 03 Nov 2026 Direct
Fred Hassan RXRX Class A Common Stock Award 156,658 156,658 02 Nov 2026 Direct
Blake Borgeson RXRX Class A Common Stock Sale -0.81% -$242,000 $4.84 -50,000 6,108,287 06 Oct 2026 Direct
Robert Hershberg RXRX Class A Common Stock Sale -13.4% -$125,000 $5.00 -25,000 162,156 06 Oct 2026 Direct
Robert Hershberg RXRX Class A Common Stock Options Exercise 15.4% 25,000 187,156 06 Oct 2026 Direct
Robert Hershberg RXRX Stock Option (Right to Buy) Options Exercise -4.76% -25,000 500,000 06 Oct 2026 Direct
Zavain Dar RXRX Class A Common Stock Award 1.91% 4,607 245,371 01 Oct 2026 Direct
Dean Y. Li RXRX Class A Common Stock Award 0.23% 3,378 1,476,707 01 Oct 2026 Direct
Ben R. Taylor RXRX Class A Common Stock Tax liability -0.5% -5,396 1,071,462 15 Sep 2026 Direct
Najat Khan RXRX Class A Common Stock Sale -1.07% -$78,822 $3.52 -22,408 2,072,890 08 Sep 2026 Direct
Blake Borgeson RXRX Class A Common Stock Sale -0.48% -$100,200 $3.34 -30,000 6,158,287 01 Sep 2026 Direct
Najat Khan RXRX Class A Common Stock Tax liability -3.7% -80,498 2,095,298 17 Aug 2026 Direct
David Hallett RXRX Class A Common Stock Tax liability -2.49% -26,657 1,043,837 17 Aug 2026 Direct
Ben R. Taylor RXRX Class A Common Stock Tax liability -2.27% -25,018 1,076,858 17 Aug 2026 Direct
Blake Borgeson RXRX Class A Common Stock Sale -0.48% -$97,500 $3.25 -30,000 6,188,287 04 Aug 2026 Direct
Blake Borgeson RXRX Class A Common Stock Sale -0.64% -$158,500 $3.96 -40,000 6,218,287 07 Jul 2026 Direct
Zavain Dar RXRX Class A Common Stock Award 2.17% 5,109 240,764 01 Jul 2026 Direct
Dean Y. Li RXRX Class A Common Stock Award 0.25% 3,747 1,473,329 01 Jul 2026 Direct
Namandje Bumpus RXRX Class A Common Stock Sale -3.01% -$12,602 $3.18 -3,963 127,632 18 Jun 2026 Direct
Blake Borgeson RXRX Class A Common Stock Award 1.43% 88,424 6,258,287 17 Jun 2026 Direct
Robert Hershberg RXRX Class A Common Stock Award 119.9% 88,424 162,156 17 Jun 2026 Direct
Franziska Michor RXRX Class A Common Stock Award 69.6% 88,424 215,477 17 Jun 2026 Direct
Elaine D. Sun RXRX Class A Common Stock Award 185.9% 88,424 135,981 17 Jun 2026 Direct
Zavain Dar RXRX Class A Common Stock Award 60.1% 88,424 235,655 17 Jun 2026 Direct
Dean Y. Li RXRX Class A Common Stock Award 6.4% 88,424 1,469,582 17 Jun 2026 Direct
Namandje Bumpus RXRX Class A Common Stock Award 204.8% 88,424 131,595 17 Jun 2026 Direct
Ben R. Taylor RXRX Class A Common Stock Tax liability -0.49% -5,396 1,101,876 15 Jun 2026 Direct
Christopher Gibson RXRX Class A Common Stock Sale -4.33% -$144,800 $3.62 -40,000 883,735 05 Jun 2026 Direct
Christopher Gibson RXRX Class A Common Stock Conversion of derivative security 4.53% 40,000 923,735 05 Jun 2026 Direct
Christopher Gibson RXRX Class B Common Stock Conversion of derivative security -0.93% -40,000 4,263,334 05 Jun 2026 Direct
Najat Khan RXRX Class A Common Stock Sale -1.07% -$84,459 $3.58 -23,588 2,175,796 05 Jun 2026 Direct
Namandje Bumpus RXRX Class A Common Stock Sale -9.22% -$15,526 $3.54 -4,386 43,171 03 Jun 2026 Direct
Blake Borgeson RXRX Class A Common Stock Sale -0.48% -$110,400 $3.68 -30,000 6,169,863 02 Jun 2026 Direct
Christopher Gibson RXRX Class A Common Stock Sale -4.33% -$123,200 $3.08 -40,000 883,735 22 May 2026 Direct
Christopher Gibson RXRX Class A Common Stock Conversion of derivative security 4.53% 40,000 923,735 22 May 2026 Direct
Christopher Gibson RXRX Class B Common Stock Conversion of derivative security -0.92% -40,000 4,303,334 22 May 2026 Direct
David Hallett RXRX Class A Common Stock Tax liability -2.43% -26,657 1,070,494 15 May 2026 Direct
Najat Khan RXRX Class A Common Stock Tax liability -2.77% -62,701 2,199,384 15 May 2026 Direct
Christopher Gibson RXRX Class A Common Stock Tax liability -2.52% -22,821 883,735 15 May 2026 Direct
Ben R. Taylor RXRX Class A Common Stock Tax liability -2.21% -25,018 1,107,272 15 May 2026 Direct
Christopher Gibson RXRX Class A Common Stock Gift -2.16% -20,000 906,556 07 May 2026 Direct
Christopher Gibson RXRX Class A Common Stock Sale -4.14% -$134,800 $3.37 -40,000 926,556 07 May 2026 Direct
Christopher Gibson RXRX Class A Common Stock Conversion of derivative security 6.62% 60,000 966,556 07 May 2026 Direct
Christopher Gibson RXRX Class B Common Stock Conversion of derivative security -1.36% -60,000 4,343,334 07 May 2026 Direct
Blake Borgeson RXRX Class A Common Stock Sale -0.48% -$105,600 $3.52 -30,000 6,199,863 05 May 2026 Direct
Christopher Gibson RXRX Class A Common Stock Sale -4.23% -$144,400 $3.61 -40,000 906,556 22 Apr 2026 Direct
Christopher Gibson RXRX Class A Common Stock Conversion of derivative security 4.41% 40,000 946,556 22 Apr 2026 Direct
* marks a reported price that did not pass the local price check.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .